Osiris Therapeutics, Inc.

Sarah Boslaugh

OSIRIS THERAPEUTICS, INC. (Osiris), is a private company founded to commercially develop therapeutic products using stem cells from adult bone marrow (mesenchymal stem cells, or MSCs), which have demonstrated the ability to repair various types of tissue within the human body and may be effective treatments for many diseases and conditions. Osiris uses proprietary stem cell technology to manufacture adult stem cells from donor marrow while maintaining their healthy, functioning state and preserving their multipotential characteristics (ability to give rise to other types of cells). The management team for Osiris (as of October 2007) includes President and Chief Executive Officer C. Randal Mills, Ph.D.; Chief Operating Officer Harry E. Carmitchel, M.B.A.; Chief Financial Officer Carey J. Claiborne; and a five—member board of directors chaired by Peter Friedli. The lead investor in Osiris is Friedli Corporate Finance, a Swiss venture capital firm directed by Peter Friedli. Osiris has two facilities, in ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.